---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-002739"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-05-15T20:27:48+00:00"
generated_at: "2026-05-15T20:33:33.627526+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Silexion Therapeutics enters inducement agreement for exercise of ~2M warrants at $0.50, raising ~$1M

## Summary
- Holders of 1,995,092 existing warrants (Series A/B at $4.00, Prior Inducement at $11.32) agree to exercise at reduced price of $0.50 per share.
- Gross proceeds of approximately $1.0 million expected from the warrant exercise, with H.C. Wainwright as placement agent earning 7% cash fee.
- Company will issue new Series C (2,045,000) and Series D (1,945,184) warrants exercisable at $0.50, totaling 3,990,184 new warrant shares.
- Closing expected on or about May 18, 2026, with net proceeds used for general corporate purposes.
- Placement agent also receives warrants to purchase up to 139,656 ordinary shares at $0.625 per share.

## SEC filing metadata
- accession: 0001178913-26-002739
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-05-15T20:27:48+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326002739/0001178913-26-002739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326002739/zk2635351.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-002739
- JSON: https://secwatch.observer/filing/0001178913-26-002739.json
- Plain text: https://secwatch.observer/filing/0001178913-26-002739.txt

## Key facts
- Material Agreements
  Silexion Therapeutics Corp entered into Inducement Letter with certain holders valued at approximately $1.0 million (effective 2026-05-15).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain holders
  - Value: approximately $1.0 million
  - Effective: 2026-05-15
  source text: On May 15, 2026, Silexion Therapeutics Corp (“ Silexion ” or the “ Company ”) entered into an inducement offer letter agreement (the “ Inducement Letter ”) with certain holders (each a “ Holder ”) of 1,995,092 of the Company’s existing warrants
  evidence_url: https://www.sec.gov/Archives/edgar/data/2022416/000117891326002739/0001178913-26-002739-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.